NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

United Therapeutics Corporation (UTHR) Stock Analysis

United Therapeutics Corporation (UTHR) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

UTHR

$487.61

−$2.63 (−0.54%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare UTHR with… →

UTHR Key Statistics

As of Sep 4, 2026
Trading
Open
$484.33
Previous Close
$490.24
Day's Range
484.33–494.09
52-Week Range
388.73–609.35
Volume
327.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.56
Valuation
Market Cap
$20.91B
P/E Ratio
17.57
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
16.24
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.22
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.63
EPS (ttm)Profit attributable to each share over the last twelve months.
27.75
Financials (FY)
Revenue (FY)
$3.18B+10.61%
Net Income (FY)
$1.33B+11.68%
Profit marginThe share of revenue left as profit after all costs and taxes.
41.56%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
42.89M
1-Year Return
+28.16%
Dividend and dates
Earnings Date
October 28, 2026estimated
Avg Volume
517.16K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

UTHR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.07%
2025+38.09%
2024+60.46%
2023−20.93%
2022+28.70%
2021+42.35%
2020+72.33%
2019−19.12%
2018−26.39%
2017+3.15%
2016 (partial year)+12.20%

As of September 4, 2026.

UTHR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.18B$1.33B41.9%
2024$2.88B$1.20B41.5%
2023$2.33B$984.80M42.3%
2022$1.94B$727.30M37.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.18B$2.80B$1.52B$1.33B41.9%
2024$2.88B$2.57B$1.45B$1.20B41.5%
2023$2.33B$2.07B$1.18B$984.80M42.3%
2022$1.94B$1.78B$979.70M$727.30M37.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

UTHR Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricUTHRDrug Manufacturers - Specialty & Generic medianvs median
P/E17.5719.279% below
P/S ratio6.632.30189% above
Profit margin41.56%−3.14%44.7 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

United Therapeutics Corporation (UTHR) carries a market capitalisation of $20.91B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 1,400 employees.

The most recent close on file for UTHR is $487.61, dated September 4, 2026. That is −$2.63 (−0.54%) against the previous close. The 52-week range on file runs from $388.73 to $609.35. The latest close sits 25.44% above that 52-week low.

Financial Health

In fiscal 2025, United Therapeutics Corporation reported revenue of $3.18B. That is +10.61% against the prior fiscal year, when revenue was $2.88B. The same year closed with net income of $1.33B. That is +11.68% against the prior fiscal year. The reported profit margin is 41.56%. That is 44.7 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to 27.75.

Across the 4 fiscal years on file, revenue moves from $1.94B in 2022 to $3.18B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

UTHR trades at a trailing price-to-earnings ratio of 17.57. That is 8.8% below the Drug Manufacturers - Specialty & Generic median of 19.27. The forward P/E on file is 16.24. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.22. The price-to-sales ratio is 6.63. On price-to-sales that is 188.72% above the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year price return is +28.16%. Measured over 10 years, that is +14.78% a year compounded. Beta against the wider market is reported at 0.56. Annualized volatility over the trailing 10 years is 34.93%.

Growth & Income

The record shows no dividend for UTHR.

Across the complete calendar years on file, 2020 returned +72.33% and 2018 returned −26.39%. Of the 9 complete calendar years on file, 6 finished higher. So far in 2026 the price is +0.07%.

Peer Comparison

United Therapeutics Corporation (UTHR) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
United Therapeutics Corporation UTHR $20.91B 17.6
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. United Therapeutics Corporation trades at a P/E of 17.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 VTRS

Viatris Inc.

$19.39B

 NBIX

Neurocrine Biosciences, Inc.

$15.82B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About United Therapeutics Corporation

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Visit website →